Intensity Therapeutics
Innovative cancer treatments targeting both visible tumors and unseen micro metastases for extended patient survival.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $6.6m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Intensity Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer treatments. Founded in 2012, the company aims to extend the lives of cancer patients while improving their quality of life. Intensity Therapeutics operates in the oncology market, targeting both visible solid tumors and unseen micro metastases, which are small cancerous cells that can spread throughout the body. The company's lead product, INT230-6, is currently undergoing human clinical trials to treat refractory solid tumor cancers. The business model revolves around the development and clinical testing of proprietary drug formulations, with revenue generated through partnerships, investments, and potential future sales of approved treatments. Intensity Therapeutics serves patients with advanced cancer, healthcare providers, and potential investors interested in supporting innovative cancer therapies.
Keywords: oncology, biotechnology, cancer treatment, clinical trials, solid tumors, micro metastases, INT230-6, drug development, patient survival, healthcare innovation.